Vivo Capital, LLC
PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$908.7M2026 Q3
Positions50
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.51.3%
What Changed This Quarter?
Top Holdings
PRAX
Praxis Precision Medicines
8.7%
TRVI
Trevi Therapeutics
6.7%
ERAS
Erasca
6.5%
AVBP
ArriVent BioPharma
6.0%
ABVX
Abivax S.A.
4.5%
ENTX
Entera Bio
3.9%
ACRS
Aclaris Therapeutics
3.9%
ANRO
Alto Neuroscience
3.8%
New / Increased
8 new · 5 increased
ENTXNEW
Entera Bio
3.9%
KRSANEW
Korsana Biosciences
3.1%
Blossomhill T…NEW
Blossomhill Therapeutics
3.1%
VORNEW
Vor Biopharma
1.2%
Cue BiopharmaNEW
Cue Biopharma
0.8%
CAMP
CAMP4 Therapeutics
2.5%
+31.5%
ANRO
Alto Neuroscience
3.8%
+12.5%
FTH
Faeth Therapeutics
2.8%
+17.0%
Reduced / Exited
8 reduced · 5 sold out
DYN
Dyne Therapeutics
0.9%
-67.0%
ORIC
Oric Pharmaceuticals
1.4%
-50.0%
TRVI
Trevi Therapeutics
6.7%
-17.0%
DRUG
Bright Minds Biosciences
2.3%
-25.0%
CMPX
Compass Therapeutics
0.4%
-55.9%
SVAEXIT
Sinovac Biotech
3.5%
DNTHEXIT
Dianthus Therapeutics
3.2%
GERNEXIT
Geron
1.0%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.